Cosmo Pharmaceuticals N.V (C43) — Cash Flow Quality Index
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Quality Index of 1.60x as of June 2022. Operating cash flow of €6.28 Million exceeds net income of €3.94 Million, indicating high earnings quality where cash backs reported profits. Explore C43 operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cosmo Pharmaceuticals N.V Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Cosmo Pharmaceuticals N.V across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check total reinvestment intensity of Cosmo Pharmaceuticals N.V to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year earnings quality comparison for Cosmo Pharmaceuticals N.V. For live market cap and the full company financial profile, see Cosmo Pharmaceuticals N.V market cap and net worth.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.22x | €162.41 Million | €133.24 Million | ▼ -95.8% |
| 2023 | 29.31x | €33.62 Million | €1.15 Million | ▲ +1419.7% |
| 2022 | 1.93x | €33.23 Million | €17.23 Million | ▲ +231.5% |
| 2021 | 0.58x | €12.61 Million | €21.67 Million | ▼ -48.1% |
| 2016 | 1.12x | €21.69 Million | €19.34 Million | — |